Humacyte (NASDAQ:HUMA) Lowered to “Sell” Rating by Wall Street Zen

Humacyte (NASDAQ:HUMA) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

A number of other equities analysts have also commented on the stock. Benchmark reduced their target price on shares of Humacyte from $17.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, May 14th. D. Boral Capital reissued a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a research note on Monday, June 9th. Finally, HC Wainwright assumed coverage on Humacyte in a report on Wednesday, May 14th. They set a “buy” rating and a $4.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $11.71.

Humacyte Trading Down 1.7%

NASDAQ:HUMA opened at $2.37 on Friday. The company has a market cap of $367.63 million, a price-to-earnings ratio of -1.77 and a beta of 2.00. Humacyte has a twelve month low of $1.15 and a twelve month high of $9.79. The stock has a fifty day simple moving average of $1.91 and a 200-day simple moving average of $3.14.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.09. The company had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $0.46 million. As a group, equities research analysts predict that Humacyte will post -1.27 EPS for the current fiscal year.

Insider Activity

In related news, CFO Dale A. Sander purchased 20,000 shares of Humacyte stock in a transaction dated Thursday, April 10th. The stock was purchased at an average cost of $1.53 per share, with a total value of $30,600.00. Following the transaction, the chief financial officer now owns 40,600 shares in the company, valued at approximately $62,118. The trade was a 97.09% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Kathleen Sebelius acquired 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 8th. The shares were bought at an average price of $1.32 per share, with a total value of $66,000.00. Following the completion of the purchase, the director now directly owns 91,207 shares in the company, valued at $120,393.24. The trade was a 121.34% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 83,993 shares of company stock worth $118,224. 5.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Humacyte

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in shares of Humacyte by 10.8% in the 4th quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company’s stock valued at $28,294,000 after buying an additional 543,995 shares in the last quarter. Northern Trust Corp lifted its position in Humacyte by 11.5% during the fourth quarter. Northern Trust Corp now owns 901,194 shares of the company’s stock valued at $4,551,000 after acquiring an additional 92,708 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Humacyte during the fourth quarter valued at approximately $99,000. Swiss National Bank boosted its stake in Humacyte by 5.8% in the fourth quarter. Swiss National Bank now owns 172,100 shares of the company’s stock valued at $869,000 after acquiring an additional 9,400 shares in the last quarter. Finally, CenterBook Partners LP acquired a new stake in Humacyte in the fourth quarter valued at approximately $6,463,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.